Clinical Trial Update: Efficacy and Safety of 20 mg (2 Tablets of 10mg)VAC BNO 1095 FCT on Cyclic Mastodynia and PMS [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating VAC BNO 1095 FCT for cyclic mastodynia and premenstrual syndrome was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mastodynia
• Premenstrual Syndrome

Drugs mentioned

• VAC BNO 1095 FCT

Snippet

Sponsor: Bionorica SE | Conditions: Premenstrual Syndrome, Mastodynia | Phase 3 | Status: TERMINATED